Jonathan P. Graham, insider at Amgen

Jonathan P. Graham Insider Information

EVP of Amgen
Jonathan Graham is executive vice president, general counsel and secretary, responsible for leading Amgen’s global Law function.

Before joining Amgen in 2015, Graham was senior vice president and general counsel at Danaher Corporation. He was responsible for all legal, governance, regulatory, risk, compliance, and EH&S matters. Prior to Danaher, Graham was vice president, Litigation and Legal Policy at General Electric Company and a partner at Williams & Connolly LLP in Washington, D.C.

Graham received a bachelor’s degree in Economics from Pitzer College and a J.D. from the University of Texas. He also served as a law clerk to the Honorable Joseph T. Sneed, U.S. Court of Appeals for the Ninth Circuit.

What is Jonathan P. Graham's net worth?

The estimated net worth of Jonathan P. Graham is at least $9.45 million as of May 10th, 2022. Mr. Graham owns 37,333 shares of Amgen stock worth more than $9,450,849 as of August 17th. This net worth evaluation does not reflect any other assets that Mr. Graham may own. Learn More about Jonathan P. Graham's net worth.

How old is Jonathan P. Graham?

Mr. Graham is currently 61 years old. There are 6 older executives and no younger executives at Amgen. The oldest executive at Amgen is Mr. Peter H. Griffith, Exec. VP & CFO, who is 63 years old. Learn More on Jonathan P. Graham's age.

How do I contact Jonathan P. Graham?

The corporate mailing address for Mr. Graham and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected] Learn More on Jonathan P. Graham's contact information.

Has Jonathan P. Graham been buying or selling shares of Amgen?

Jonathan P. Graham has not been actively trading shares of Amgen in the last ninety days. Learn More on Jonathan P. Graham's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & CEO), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 14,100 shares worth more than $3,414,435.00. The most recent insider tranaction occured on May, 23rd when Director R Sanders Williams sold 600 shares worth more than $150,000.00. Insiders at Amgen own 0.5 % of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 5/23/2022.

Jonathan P. Graham Insider Trading History at Amgen

See Full Table

Jonathan P. Graham Buying and Selling Activity at Amgen

This chart shows Jonathan P. Graham's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $253.15
Low: $251.66
High: $254.16

50 Day Range

MA: $245.03
Low: $230.71
High: $253.15

2 Week Range

Now: $253.15
Low: $198.64
High: $258.45

Volume

2,205,976 shs

Average Volume

2,491,898 shs

Market Capitalization

$135.42 billion

P/E Ratio

21.45

Dividend Yield

3.09%

Beta

0.56